# Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Study · id `cardio:ct-nct07257198` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07257198](<https://clinicaltrials.gov/study/NCT07257198>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07257198

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2570 participants.

## Technical summary

Registry record NCT07257198. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-03 (actual); primary completion 2030-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2570 participants (planned count; ClinicalTrials.gov record NCT07257198, source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)
- Started: 2026-03-03 (actual) (ClinicalTrials.gov record NCT07257198, source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)
- Primary completion: 2030-01-01 (anticipated) (ClinicalTrials.gov record NCT07257198, source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)
- Completion: 2031-01-01 (anticipated) (ClinicalTrials.gov record NCT07257198, source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT07257198, source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07257198-2026-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
- Acronym: PANTHEON
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Condition: STEMI (ST Elevation MI)
- Condition: Myocardial Infarction
- Intervention (Drug): Ticagrelor + placebo
- Intervention (Drug): Ticagrelor + aspirin
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)

## Provenance

Content hash: ed44a79fd0cca5069b745be25cead328499be0ca50ca0818ab04b9e74dd6515a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
